UCFA
TEVA icon

United Capital Financial Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

United Capital Financial Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.09M Sell
32,054
-1,020
-3% -$34K 0.01% 772
2026
Q1 		$996K Sell
33,074
-1,337
-4% -$43K 0.01% 759
2025
Q4 		$1.07M Buy
34,411
+118
+0.3% +$2.91K 0.01% 714
2025
Q3 		$693K Sell
34,293
-79
-0.2% -$1.39K 0.01% 761
2025
Q2 		$576K Sell
34,372
-744
-2% -$12K ﹤0.01% 745
2025
Q1 		$540K Buy
35,116
+1,833
+6% +$32.7K ﹤0.01% 728
2024
Q4 		$734K Buy
33,283
+265
+0.8% +$4.82K 0.01% 626
2024
Q3 		$595K Sell
33,018
-4,513
-12% -$79K ﹤0.01% 684
2024
Q2 		$610K Sell
37,531
-1,075
-3% -$16.6K 0.01% 654
2024
Q1 		$545K Buy
+38,606
New +$487K ﹤0.01% 718
2020
Q2 		– Sell
-13,116
Closed -$118K – 1258
2020
Q1 		$118K Buy
13,116
+1,484
+13% +$15.2K ﹤0.01% 1116
2019
Q4 		$114K Buy
11,632
+240
+2% +$2.14K ﹤0.01% 1322
2019
Q3 		$78K Buy
+11,392
New +$87.3K ﹤0.01% 1254
2017
Q4 		– Sell
-15,788
Closed -$278K – 1356
2017
Q3 		$278K Sell
15,788
-9,341
-37% -$210K ﹤0.01% 1136
2017
Q2 		$835K Sell
25,129
-964
-4% -$29.8K 0.01% 811
2017
Q1 		$837K Sell
26,093
-932
-3% -$31.8K 0.01% 794
2016
Q4 		$980K Sell
27,025
-5,351
-17% -$214K 0.01% 758
2016
Q3 		$1.49M Sell
32,376
-4,142
-11% -$216K 0.01% 666
2016
Q2 		$1.83M Sell
36,518
-58,420
-62% -$3.11M 0.02% 574
2016
Q1 		$5.08M Buy
94,938
+58,149
+158% +$3.41M 0.06% 329
2015
Q4 		$2.42M Sell
36,789
-20,812
-36% -$1.29M 0.03% 513
2015
Q3 		$3.25M Buy
57,601
+1,834
+3% +$119K 0.04% 413
2015
Q2 		$3.3M Buy
55,767
+1,129
+2% +$69.6K 0.04% 458
2015
Q1 		$3.3M Buy
54,638
+11,771
+27% +$684K 0.04% 440
2014
Q4 		$2.46M Buy
42,867
+32,996
+334% +$1.84M 0.04% 414
2014
Q3 		$531K Buy
+9,871
New +$523K 0.01% 776
2014
Q2 		– Sell
-10,445
Closed -$552K – 918
2014
Q1 		$552K Buy
10,445
+3,657
+54% +$169K 0.01% 617
2013
Q4 		$272K Sell
6,788
-19,167
-74% -$755K 0.01% 543
2013
Q3 		$981K Sell
25,955
-43,132
-62% -$1.68M 0.03% 347
2013
Q2 		$2.71M Buy
+69,087
New +$2.69M 0.07% 270

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

United Capital Financial Advisors's TEVA Position: Q2 2026 in Review

United Capital Financial Advisors reduced its Teva Pharmaceuticals (TEVA) stake by 3.1% in Q2 2026, selling an estimated $34K and leaving 32,054 shares worth $1.09M. The position accounts for 0.01% of the portfolio, ranked #772.

United Capital Financial Advisors first reported a position in TEVA in Q2 2013 and has held it in 30 quarters since. The position peaked at $5.08M in Q1 2016. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • United Capital Financial Advisors held 32,054 shares of Teva Pharmaceuticals worth $1.09M as of Q2 2026.
  • United Capital Financial Advisors sold 1,020 Teva Pharmaceuticals shares in Q2 2026, an estimated $34K.
  • Teva Pharmaceuticals made up 0.01% of United Capital Financial Advisors's portfolio in Q2 2026, its #772 holding.
  • United Capital Financial Advisors first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 30 quarters since.
  • United Capital Financial Advisors's Teva Pharmaceuticals position peaked at $5.08M in Q1 2016.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on United Capital Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.